Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial

OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-control...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Obstet Gynecol
Главные авторы: Carr, Bruce R., Stewart, Elizabeth A., Archer, David F., Al-Hendy, Ayman, Bradley, Linda, Watts, Nelson B., Diamond, Michael P., Gao, Jingjing, Owens, Charlotte D., Chwalisz, Kristof, Duan, W. Rachel, Soliman, Ahmed M., Dufek, Matthew B., Simon, James A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7963450/
https://ncbi.nlm.nih.gov/pubmed/30303923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000002933
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы